Abstract
It is a rare biotech company that can advance their product to commercialization without the help of a corporate partner or strategic alliance. A good partnership can tremendously accelerate product and market development. Not only is a strategic partner advantageous to a development-stage biotech company, but they are almost essential. In this chapter, we discuss strategic alliances, some of the pitfalls, and the value they can bring to the company.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Drug Development; Pharma-Biotech Alliances Present Lower Risk Opportunities, Drug Week (Biotech Business Week), January 5, 2004.
- 2.
Reproduced by permission from: A Marriage of Minds: Making Biopharmaceutical Collaborations Work (2007) IBM Institute for Business Value and Silico Research. Heather Fraser and Stuart Henderson.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Shimasaki, C.D. (2009). Strategic Alliances and Corporate Partnerships. In: The Business of Bioscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0064-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0064-7_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0063-0
Online ISBN: 978-1-4419-0064-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
